Trial Profile
A phase II trial of trastuzumab, Neupogen [filgrastim], and vinorelbine investigating the effects on immune function and clinical outcomes in patients with metastatic breast cancer overexpressing HER-2/neu.
Status:
Discontinued
Phase of Trial:
Phase II/III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Filgrastim (Primary) ; Trastuzumab (Primary) ; Vinorelbine (Primary) ; Granulocyte colony-stimulating factors
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 20 Oct 2011 Trial phase changed from II to II/III as reported by ClinicalTrials.gov.
- 11 Aug 2009 Actual number of patients (23) added as reported by ClinicalTrials.gov
- 11 Aug 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov